Skip to main content
. 2024 Apr 12;10(2):e003981. doi: 10.1136/rmdopen-2023-003981

Table 2. Immunosuppressive/DMARD (disease modifying anti-rheumatic drugs) therapies received before belimumab in patients not IS-naïve (n=80).

Drug Patients (%)
Azathioprine (%) 29 (36)
Mycophenolate (%) 23 (29)
Methotrexate (%) 39 (49)
Cyclophosphamide (%) 15 (19)
Cyclosporine (%) 20 (25)
Other (%) 4 (5)

ISimmunosuppressants